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Background
Uncomplicated acute rhinosinusitis (ARS) is usually a
self-limiting inflammatory condition often treated with
antibiotics. This study evaluated an alternative treatment
for symptomatic relief of uncomplicated ARS, fluticasone
furoate nasal spray (FFNS).
Methods
This randomized, double-blind, placebo-controlled, paral-
lel-group, multicenter, 2-week treatment study evaluated
FFNS 110 mcg once daily, twice daily vs. placebo in adults/
adolescents with uncomplicated ARS. Eligibility criteria
reflected a clinical diagnosis and eliminated confounding
conditions like common cold, symptomatic allergic rhinitis
(AR), and other sinonasal conditions. Subjects with daily
major symptom score (MSS; a composite score of 3 symp-
toms [nasal congestion/stuffiness, sinus headache/pressure
or facial pain/pressure, and postnasal drip on a 0-3 scale])
>4.5 at baseline were randomized.
Results
The study demonstrated a statistically significant reduc-
tion in daily MSS by both FFNS doses compared to pla-
cebo (LS mean differences vs. placebo of -0.357 [p=0.014]
and -0.386 [p=0.008] for BID and QD, respectively). The
differences in median time to symptom improvement
between placebo (8 days) and each FFNS dose (7 days)
were not statistically significant. There were no treatment
differences in antibiotic use due to the development of
possible fulminant bacterial rhinosinusitis (3% in each
group). The safety profile of FFNS was similar to placebo.
Conclusion
FFNS reduced symptoms of uncomplicated ARS com-
pared to placebo and was well tolerated, providing sup-
port for withholding antibiotics in selected patients.
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